



ASX and MEDIA Announcement

AUST ODC APPROVES NANADOL EXPORT FOR UK USE

Sydney, February 7, 2023 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company) is very pleased to announce it has received the export permit from the Australian Office of Drug Control (ODC) for NanaDol (NanaBis™ export name).

As per prior announcements, on 25th November 2022 regarding MHRA acceptance to the UK NPP and 25th January 2023 UK Home Office approvals for importation, today the Australian Office of Drug Control (ODC) has provided export certification for the lawful supply of NanaDol, the export name for NanaBis™ specifically for the United Kingdom

NanaDol will be exported to the UK where the Company's partner, WEP Clinical, will supply UK patients as appropriate. Several hundred units of NanaDol are expected to ship as soon as secure freight has been arranged.

– ENDS –

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the use of **NanoCelle**® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate **NanaBis**™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO, Medlab Clinical Ltd

T: +61 411 603 378

E: sean_hall@medlab.co